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post-ERCP pancreatitis prevention: A netwoa b s t r a c t
Objectives: Post-ERCP pancreatitis (PEP) is a life-threatening complication. Given the lack of a causative
treatment for pancreatitis, it is of vital importance to minimize this risk of PEP. Multi-target preventive
therapy may be the best choice for PEP prevention as disease development is multifactorial.
Aim: We aimed to assess the efficacy of a combination of indomethacin and hydration e type and
amount e for PEP prevention via a network meta-analysis.
Methods: Through a systematic search in three databases, we searched all randomized controlled trials
involving hydration and indomethacin and ranked the PEP preventive efficacy with a Bayesian network
meta-analysis using the PRISMA for Network Meta-Analyses (PRISMA-NMA) guideline. The RoB2 tool
was used for risk of bias assessment, surface under the cumulative ranking curve (SUCRA) for ranking
and PROSPERO for the study protocol [reg. no. CRD42018112698]. We used risk ratios (RR) for dichot-
omous data with 95% credible intervals (95% CrI).
Results: The quantitative analysis included 7559 patients from 24 randomized controlled trials. Based on
the SUCRA values, a combination of lactated Ringer's and indomethacin is more effective than single
therapy with a 94% certainty. The percent relative risk ratios estimate preventive efficacy 70e99% higher
for combinations than single therapies. Aggressive hydration with indomethacin (SUCRA 100%) is also
significantly more effective than all other interventions (percent relative effect 94.3e98.1%).
Conclusions: A one-hit-on-each-target therapeutic approach is recommended in PEP prevention with an
easily accessible combination of indomethacin and aggressive hydration for all average and high-risk
patients without contraindication.
© 2021 Published by Elsevier B.V. on behalf of IAP and EPC.ses, Heart and Vascular Cen-
apest, Hungary.
(P. Hegyi).
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Endoscopic retrograde cholangiopancreatography (ERCP) is
predominantly a therapeutic procedure for biliary or pancreatic
duct-associated diseases. According to the American Gastroenter-
ological Association (AGA), more than 650 000 ERCP procedures are
carried out each year in the U.S [1]. The most common and fearedof indomethacin and hydration is the best conservative approach for
gy, https://doi.org/10.1016/j.pan.2021.07.005
Abbreviations
AGA American Gastroenterological Association
AP acute pancreatitis
ASGE American Society for Gastrointestinal Endoscopy
AV aggressive volume (3mL/kg/h during ERCP, 20mL/
kg bolus after ERCP and 3 mL/kg/h for 8 h after
ERCP)
CrI credible intervals
ERCP endoscopic retrograde cholangiopancreatography




NSAID nonsteroidal anti-inflammatory drugs
NT no treatment (i.e. placebo)
NV normal volume (1.5 mL/kg/h during ERCP plus 8 h)
PEP post-ERCP pancreatitis
RCT randomized controlled trial
RoB risk of bias
RR risk ratio
SUCRA surface under the cumulative ranking curve
Table 1
PICOS criteria.
P patient undergoing ERCP
I & C IND e indomethacin;
LR e lactated Ringer's;
NS e normal saline;
AV e aggressive volume;
NV e normal volume;





O Post e ERCP pancreatitis
S RCT
Table 2
Chemical composition of NS and LR. Higher cc. of chloride may cause hyper-
chloremic acidosis in NS solution. Otherwise, lactate lowers the risk of acidosis, thus
guaranteeing substrates for the biocarbonate base in pH balanced LR. NS e normal
saline; LR e lactated Ringer's.
Ingredients Saline Lactated Ringer's
Sodium (mEq/liter) 154 131
Chloride (mEq/liter) 154 110
Potassium (mEq/liter) 0 4e5
Calcium (mEq/liter) 0 3
Lactate (mEq/liter) 0 28
Osmolarity (mOsmol/liter) 308 273
pH 5.6 6.5
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cases [2e6], and <10% of those can be severe or even life-
threatening [4e6] with an annual estimated cost that exceeds
$200 million in the U.S [2,3].
Both the European and American Societies of Gastrointestinal
Endoscopy (ESGE, ASGE) recommend preventive therapies to lower
the risk of PEP development with various levels of evidence [7e9].
Importantly, microcirculatory insufficiency and inflammation were
defined as key elements in the pathophysiology of pancreatitis
[10e13]. Subsequently, attempts weremade to lower the risk of PEP
by means of pre-procedural administration of an anti-
inflammatory drug and by pro-actively correcting possible hypo-
volemia. In recent decades, researchers paid closer attention to
fluid replacement in basic research and clinical trials as well. The
recently published network meta-analyses comparing different
preventive techniques, however, did not distinguish between the
type and volume of fluid supplementation [14e16].
In this study we performed a network meta-analysis of ran-
domized controlled trials (RCTs) involving PEP prevention with
hydration and the most widely used NSAID suppository, in casu
indomethacin (IND), to evaluate the efficacy of each strategy
separately and combined in order to aid clinicians in their decision
making which preventive strategy to use.
2. Methods
2.1. Protocol and registration
The study was registered in the PROSPERO database [reg. no.
CRD42018112698], and the PRISMA-NMA guideline was followed
from study preparation to manuscript finalization [17].
2.2. PICO and eligibility
The PICOS format (patient, intervention, comparison, outcome
and study design) was applied to define our research (Table 1).
Inclusion criteria were a) involvement at least two interventions of
our interest with at least 10 patients above 18 years of age in RCT, b)
without limitation of risk for PEP, and b) additional pharmaceutical2
treatments were exclusion criteria.
2.3. Search
A systematic literature search was conducted to identify all RCTs
on PEP prevention in three databases: MEDLINE (via PubMed),
Embase and the Cochrane Central Register of Controlled Trials
(CENTRAL). The keywords in the literature search were ‘post-ERCP
pancreatitis and prevention’ from inception to May 2020 without
any restrictions (searching MeSH via PubMed; post-ercp[All Fields]
AND (“pancreatitis"[MeSH Terms] OR “pancreatitis"[All Fields])
AND (“prevention and control"[Subheading] OR (“prevention"[All
Fields] AND “control"[All Fields]) OR “prevention and control"[All
Fields] OR “prevention"[All Fields])).
2.4. Selection and data extraction
Full-text articles and conference abstracts were included in the
synthesis. Duplicates were excluded in reference manager software
(Endnote), with titles and abstracts then selected by two inde-
pendent authors (KM and ZS). In the case of disagreement, a third
author made the final decision (PH). Data was collected in an Excel
file for synthesis in two groups with six interventions each (KM, ZS
and PH in the case of disagreement). In Group I IND monotherapy
was compared to crystalloids and their combinations; LR, NS,
LR þ IND, NS þ IND and NT. In Group II we examined the relevance
of fluid amount, the comparators for IND were therefore; AV, NV,
AV þ IND, NV þ IND and NT (see network plots in Figs. 1 and 3,
additional details in Sup Table 1). IND and NT were two treatments
that were possible to include in both Group I and II analyses.
2.5. Risk of bias assessment
The risk of bias in randomized trials (RoB) of all included articles
was assessed using the revised RoB 2 tool [18] (KM, ZS and PH in the
case of a disagreement) (Sup Table 2).
Fig. 1. Characteristics of network for fluid quality measurements. A Data for 17 articles comparing different interventions to prevent post-ERCP pancreatitis (efficacy outcome). Two-
arm studies compared two interventions, while multi-arm studies compared four treatments (in two studies) and three treatments (in one study). B Intervention groupwise data
characteristics. C Comparison features between arms. D Network plot of randomized controlled trials. Nodes are the different interventions weighted according to the number of
studies with the respective interventions. Edges represent the direct comparisons weighted according to the number of studies testing the comparators. LR e lactated Ringer's; NS e
normal saline; IND e indomethacin, NT e no treatment.
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A Bayesianmethodwas used to perform pairwisemeta-analyses
and NMAswith the random effect model. The NMA takes advantage
of two statistical innovations; 1) the evaluation of indirect com-
parisons; therefore, we can estimate the effect of ‘A’ vs. ‘B’ indirectly
if both ‘A’ and ‘B’ is compared to ‘C’; 2) the NMA combine direct and
indirect comparisons and provide estimates of the relative effect of
every alternative versus every other alternative [19]. We tested
consistency with node splitting, when the associations are analysed
between the direct and indirect comparisons [20]. We used risk
ratios (RR) for dichotomous data with 95% credible intervals (95%
CrI) and percent relative effect. We optimized the model and
generated posterior samples using Monte Carlo methods running
in four chains. We set at least 20 000 adaptation iterations to obtain
convergence and 10 000 simulation iterations. We also ranked in-
terventions with posterior probability by calculating the surface
under cumulative ranking (SUCRA) curve values. The higher the
SUCRAvalue, and the closer to 100%, the higher the likelihood that a
therapy is in the top rank or one of the top ranks; the closer to 0 the
SUCRAvalue, themore likely that a therapy is in the bottom rank, or
one of the bottom ranks [21]. All calculations were performed with
R (V. 3.5.2) package gemtc (V. 0.8e2) along with the Markov Chain
Monte Carlo engine JAGS (V. 3.4.0) and STATA 17.0 (StataCorp LLC)
[22].
3. Results
The database search yielded 1011 records that underwent a3
rigorous selection process (see Methods) (Sup Fig. 1). Data from 24
RCTs including 7559 patients were analysed in this study; 17 RCTs
comparing different fluid types (Group I) [23e39] and 23 RCTs
reporting on different fluid quantities that were used (Group II)
[23e37,40e46] (Figs. 1 and 3).
Originally, we planned to investigate the efficacy of indometh-
acin, lactated Ringer's and combination of these. Our search strat-
egy gave an opportunity to add further interventions; therefore, we
included normal saline and fluid volume as well. We did not have
enough data to investigate one outcome of our interest, the severity
of PEP.
3.1. Group I
Out of the 15 possible comparisons, articles contained data for
14 direct pairwise comparisons with the exception of the LR þ IND
vs NTgroup, meaning that these two interventions have never been
examined in parallel in a randomized study design.
617 subjects out of 6208 ERCPs developed PEP (10.15%). The
majority of the patients were involved in the IND vs NT group with
almost 4600 cases from 11 studies (Fig. 1C) [24e30,32,34,35,37].
A forest plot of summarized data shows the level of difference
between the treatments (Sup Fig. 2). RR > 1 and CrI>1 demonstrate
that LR þ IND and NS þ IND significantly reduced the frequency of
PEP compared to all treatments. This analysis reveals that a com-
bination of fluid and anti-inflammatory therapy is significantly
more effective in PEP prevention than either single treatment.
Moreover, the ranks based on the SUCRA values indicate a
greater importance of hydration in prevention and also suggest that
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nation (94% vs 85%) and single use (52% vs 46%) (Fig. 2A). It is worth
mentioning that the administered fluid amounts were very similar
(Fig. 2A). The percent relative effect was calculated from risk ratio
estimates, proving that the efficacy in PEP prevention is 70e99%
higher for combinations compared to single therapies. Risk ratio
estimates are showed in Fig. 2C, calculation was made with a
formula;
percent realive effectð%Þ¼ ð1 risk ratio estimate Þ*100
e.g. the percent relative effect of LR þ IND compared to LR equals;
1e0.21*100, therefore 79%.
Of note, a limitation should be acknowledged that comparability
tests between direct, indirect and estimated comparisons show
significant differences, meaning that a future RCT might lead to
different results than is estimated by the network. This uncertainty
is based on a zero event in one study [28] (NT vs NS þ IND; direct
OR 5.9eþ7 (53, 5.7eþ17), indirect OR 7.6 (2.8, 24), network OR 12
(4.6, 33) p ¼ 0.005).3.2. Group II - quantity
Although more RCTs were identified that compared various
amounts of fluid replacement, fewer comparisons were examined:
we were able to carry out eight out of the possible 15 pairwise
comparisons (Fig. 3). Nevertheless, the network study design with
indirect calculations is suited to estimate the difference between
the arms without direct treatment comparisons, meaning that it is
possible to estimate outcomes of treatments that have never been
directly compared to each other. An inconsistency test shows
comparability between the estimated, indirect and direct compar-
isons, showing that a RCT is likely conclude the same as is estimatedFig. 2. Interventions with the possibility of being ranked from best to worst efficacy in PEP
ranked from best to worst based on the SUCRA values. The table at the bottom lists the
comparability considerations. B The analysis shows the probability of all interventions to m
SUCRA value is, the higher the likelihood that a therapy is in the top rank; the closer to 0 it is
for each pair of interventions accompanied by 95% CrI according to the efficacy of PEP prev
normal saline; IND e indomethacin; NT e no treatment; AV e aggressive volume; NV e norm
e surface under the cumulative ranking curve.
4
by the network. The inconsistency test showed that all estimates
are probably true predictions (AV vs AV þ IND: direct OR 8.8e-29
(4.2e-64, 0.0012), indirect OR 3.3e-12 (9.2e-33, 0.11), network OR
2.6e-14 (2.2e-49, 0.0088) p ¼ 0.3225; NT vs AV þ IND: direct OR
1.2eþ8 (58, 1.2eþ44), indirect OR 3.5eþ12 (21, 1eþ32), network OR
9.7eþ13 (2.8eþ2, 1.3eþ49) p ¼ 0.828).
A forest plot of summarized data presents the level of difference
between the treatments as non-significantly or significantly worse
or better or equal (Sup Fig. 3). RR > 1 and CI > 1 demonstrate that
AV þ IND significantly reduced the frequency of PEP compared to
other treatments. NVþ IND is significantly worse in preventing PEP
compared to AV þ IND and is equal to all other treatments. The
efficacy of AV þ IND is well represented by the SUCRA value-based
ranking (Fig 4AB). The percent relative effect was calculated from
risk ratio estimates, which show a superior efficacy (94.3e98.1%) in
PEP prevention for the combination of AV and IND. Risk ratio es-
timates are showed in Fig. 4C, calculationwasmadewith a formula;
percent realive effectð%Þ¼ ð1 risk ratio estimate Þ*100
e.g. the percent relative effect of AV þ IND compared to NV þ IND
equals; 1e0.057*100, therefore 94.3%.4. Discussion
According to the latest guidelines, there is currently no causative
treatment for pancreatitis; only supportive therapy and
complication-preventive interventions are recommended [7,8,47].
Hence, those measures should be instituted that have the potency
to prevent the development of the disease, based on either gener-
ally applicable or aetiology-based preventive principles. PEP is a
complication of a therapeutic intervention; aetiology-based pre-
vention is therefore not feasible because the therapy itself injureprevention. A Probability chart showing likelihood in percentage of treatments being
amount of fluid that was administered in the cited study and the outcome rate for
atch the top rank with a numerical representation of the SUCRA. The closer to 1 the
, the more likely that a therapy is in the bottom rank. C League table with RR estimates
ention (*significant difference where RR < 1 and CrI<1). LR e lactated Ringer's; NS e
al volume; PEP e post-ERCP pancreatitis, RR e risk ratio, CrI e credible interval, SUCRA
Fig. 3. Characteristics of network for fluid quantity measurements. A Data from 23 included articles. Two-arm studies compared two interventions, while multi-arm studies
compared four treatments (in one study) and three treatments (in another). B Intervention groupwise data characteristics. C Comparison features between arms. D Network plot of
randomized controlled trials comparing different interventions to prevent post-ERCP AP (efficacy outcome). Nodes are weighted according to the number of studies with the
respective interventions. Edges are weighted according to the number of studies testing the comparators. AV e aggressive volume; NV e normal volume; IND e indomethacin, NT e
no treatment.
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cellular damage caused by the contrast media (pressure and
chemical reaction), these two mechanism can not be avoided,
however the damage can be decreased to a minimum level.
In ERCP the mechanical insult causes obstruction of the main
pancreatic duct (mostly due to oedema and mechanical injury due
to guidewiremanipulation), triggering the inflammatory processes.
If the obstruction and its consequences are efficiently prevented
the pancreas might be saved from PEP. Stent insertion and
epinephrine injection might be a solution to ameliorate the
obstruction. Stent insertion maintains outflow of the pancreatic
juice while epinephrine injection decreases the oedema through
vasoconstriction and relaxing the oddi sphinchter, however none of
them have effect on the launched cellular damage (see Graphical
abstract).
Themechanical prevention has beenwell investigated and there
is quite strong agreement concerning the benefit of pancreatic duct
stent insertion across guidelines [7e9]. Pancreatic stenting has
proved to be efficient in PEP prevention; however, the success rate
is dependent on the operator's skills to achieve swift pancreatic
duct cannulation and the ductal anatomy of the pancreas. Those
factors might be a reason for the wide PEP incidence range among
studies in the literature and in this network meta-analysis (Figs. 2A
and 4A). After multiple attempts, the risk of AP is significantly
elevated; therefore, we only recommend this technique in selected
cases, especially with inadvertent guidewire insertions into the
pancreatic duct. We also need to mention that there is no agree-
ment on the types of pancreatic stents, e.g. pigtail, diameter, flaps
no flaps, etc. to be used for PEP prevention. In the current manu-
script therefore, we decided to focus on the evaluation of non-
invasive and relatively easy to apply techniques for PEP preven-
tion (i.e., IND and fluid therapy) which are universally applicable
independent from operator expertise. The focus of this paper is to5
compare the fluid variants (type and quantity) as an addition to the
recently published network meta-analyses [14e16,48]. None of
these studies differentiated between lactated Ringer's or normal
saline, and aggressive or normal volume [14e16].
The newly established ESGE 2020 guideline's algorithm for PEP
prophylaxis prioritizes NSAID and suggests considering hydration
only when NSAID is contraindicated [9]. Interestingly a recent
network meta-analysis revealed that rectally administered indo-
methacin or diclofenac is not only efficient in high-risk patients to
prevent PEP but the efficacy equals placement of a pancreatic stent
[49].4.1. One of the most important factors in PEP development is the
microcircular insufficiency
In the earliest stage of PEP development, there is a microcircu-
latory impairment due to an increased parenchymal pressure that
is propagated by the high pressure within the obstructed pancre-
atic duct by bouts of contrast injection and later on due to (tem-
porary) outflow obstruction caused by papillary oedema. The
impaired fluid distribution is reparable with fluid substitution as it
maintains perfusion of the small vessels, thus lowering the risk of
hypoxia, reactive oxygen species generation and mitochondrial
injury. The most commonly used fluid infusions for volume
expansion are normal saline and lactated Ringer's infusions. It is
therefore important to understand their main differences, potential
benefits, and disadvantages. Normal saline is a hypertonic acidotic
fluid containing higher sodium and chloride than lactated Ringer's,
which carries the risk of hyperchloremic acidosis (Table 2).
On the other hand, LR also contains sodium lactate, which is
metabolized by the liver, producing bicarbonate as a base to reduce
acidity (Table 2) [50]. Rumbus et al. examined the correlation be-
tween acidosis and pancreatitis in an experimental model and on
Fig. 4. Interventions with the possibility of being ranked from the best to the worst efficacy in PEP prevention. A Probability chart showing the likelihood in percentage of
treatments ranked from best to worst based on the surface under the cumulative ranking curve (SUCRA). The table below lists the type of fluid administered in the cited study and
the rate of outcome for comparability considerations. B The analysis shows the probability of all interventions to match the top rank with a numerical representation of the SUCRA.
The closer to 1 the SUCRA value is, the higher the likelihood that a therapy is in the top rank; the closer to 0 it is, the more likely that a therapy is in the bottom rank. C Risk ratio
estimates for each pair of interventions accompanied by 95% CI according to the efficacy of PEP prevention (*significant difference where RR < 1 and CrI<1). AV e aggressive
volume; NV e normal volume; IND e indomethacin; NT e no treatment; LR e lactated Ringer's; NS e normal saline; PEP e post-ERCP pancreatitis.
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the severity of acute pancreatitis (AP) while severe AP further
decreased the blood pH, causing a vicious circle [51]. Kellum et al.
also called attention to the importance of acidity in inflammation
development when they observed that the level of pro-
inflammatory cytokines was increased in septic rats with hyper-
chloremic acidosis [52]. In an abdominal sepsis animal model,
resuscitationwith NS was associated with hyperchloremic acidosis,
a more altered microcirculation leading to greater haemodynamic
instability and more severe organ dysfunction. In this study, the
survival time was significantly longer in the LR group compared to
the NS group (17 h [14 to 20] vs 26 h [23 to 29], p < 0.01) [53].4.2. Besides the composition of the fluid replacement, timing and
fluid quantity are also intensively investigated
While an adequate volume of fluid replacement is essential to
restoring perfusion and oxygenation, fluid overload on the other
handmight cause complications, such as cardiac failure, pulmonary
oedema, tissue damage and impaired bowel function [54]. How-
ever, carefully monitored aggressive intravenous fluid replacement
therapy was found more effective in avoiding the negative6
outcomes of AP in meta-analyses of RCTs [55e58]. The latest
guidelines for AP treatment suggest fluid therapy as the first step
after AP diagnosis because its beneficial effect is maximal in the
first 24 h of disease development [47,59,60]. ‘The sooner, the better’
might therefore be a rational approach in PEP prevention as long as
there are no contraindication.
Recent RCTs also suggest the efficacy of early aggressive fluid
therapy in PEP prevention. In an RCT, Alcivar-Leon et al. investi-
gated the preventive efficacy of AV LR compared to NV NS and
showed a statistically significant and clinical favourable effect of
the former in PEP prevention (3.4% and 87%, respectively, RR 0.41;
95% CI 0.20e0.86; p ¼ 0.016) [23]. Park et al. also found significant
differences in comparing AV LR to AV NS and NV LR groups (3.0%,
95% CI 0.1e5.9 vs 6.7%, 95% CI 2.5e10.9 vs 11.6%, 95% CI 6.1e17.2,
p ¼ 0.03) [33]. The quantitative importance of fluid substitution is
shown with lower RR in PEP rate for the AV LR group (0.26) rather
than for the NV LR group (95% CrI 0.08e0.76; p ¼ 0.008). With
reference to the importance of a balanced solution, this study
resulted in no superiority of AV NS treatments to NV LR (RR 0.57,
95% CI 0.26e1.27; p ¼ 0.17) [33].
When Masjedizadeh et al. compared AV LR and IND treatments
to control cases, it was concluded that LR is the most effective
Table 3
Summary of PEP prophylaxis based on available guidelines and our newly established recommendations in bold.
Implementation to practice Patient's risk of PEP
High risk All risks
Stent Strongly considered3 Recommended4 NA
Indomethacin Recommended3 Recommended3,4
Hydration Suggested
Hydration and indomethacin Suggested
K. Marta, N. Gede, Z. Szakacs et al. Pancreatology xxx (xxxx) xxxintervention in PEP prevention (p ¼ 0.036) [30].4.3. Despite preventive efforts, if inflammation develops, the
severity of the processes might be mitigated due to the interruption
of the inflammatory cascade with anti-inflammatory drugs [61]
Nonsteroid anti-inflammatory drugs (NSAIDs) are widely pre-
scribed to treat inflammatory diseases like arthritis (rheumatoid
arthritis, osteoarthritis and gout), bursitis and tendinitis. Their ef-
ficacy is due to the inhibition of cyclo-oxygenase, which is
responsible for prostaglandin and thromboxane formation from
arachidonic acid-triggering inflammation [62].
Diclofenac and indomethacin are the two mostly investigated
and used NSAIDs in the prevention of PEP and are compared in 11
meta-analyses to date. These MAs conclude that both have signif-
icant efficacy [63e72], in average-risk and high-risk patients aswell
[63,66,67,69,71], and that non-rectal administration like oral,
intramuscular or intravenous are not efficient [63,66e68,70,71]. In
addition, four more NSAIDs (valdecoxib, celecoxib, naproxen,
ketoprofen) are examined in meta-analyses [66,68,70,73e75] of
which only naproxen showed to be effective in PEP prevention [66].
In the current manuscript we focus on indomethacin because it
provided the possibility to include hydration to this network meta-
analysis.
In addition to the documented pharmacological effect of
NSAIDs, efficacy for PEP prevention varies widely between studies.
Choksi et al. found a positive correlation between the prevention of
PEP and indomethacin usage, Moon et al. and Andrade-Davila et al.
found significantly fewer episodes in the indomethacin group
compared with the placebo group (p ¼ 0.005 and p ¼ 0.01,
respectively), and in a study by Elmunzer et al. indomethacin
significantly reduced the occurrence and severity of PEP (p ¼ 0.005
and p ¼ 0.03) [24,27,36,37]. Studies by D€obr€onte et al. Montano
et al. and Levenick et al. however, did not find indomethacin
effective for PEP prevention [25,26,29,32]. Sotoudehmanesh et al.
reported that IND was ineffective in PEP prevention; however, a
significant effect was shown in severity reduction [35].
Studies inwhich INDwas used for PEP prevention, all with rectal
application to lower the risk of side-effects, reported no higher risk
of bleeding [24,27,29,31,34,35]. The absorption peak concentration
of 30 min to 1 h and elimination half-life of 6e8 h allow rectally
administered IND to be effective when added before or after ERCP
[76].4.4. The question arises whether the efficacy is further increased if
volume expansion and NSAIDs are combined
There is much less uncertainty about the efficacy of IND when
used in combinationwith fluid treatments. Selimah et al. examined
combined fluid and drug treatment and found a positive effect for
AV LR solutionwith IND compared to IND alone [39]. Hosseini et al.
compared (1) IND, (2) NS and (3) an IND and NS combination to (4)
a placebo and found that PEP could be significantly prevented if the
combination was used [28]. In a different design, where (1) NS, (2)7
NS þ IND, (3) LR and (4) LR þ IND were compared by Mok et al. it
was also concluded that LR þ IND was significantly more effective
in PEP prevention than any other condition [31].
Considering the different pathological pathways and conse-
quences of increased ductal pressure, impaired microcirculation
and inflammation, a multi-facetted ‘one-hit-for-each-target’ seems
a rational approach attempting to prevent PEP. Its potential benefit
is dependent on the different modes of action of each individual
intervention with microcirculatory reperfusion restoring adequate
blood supply and oxygenation and anti-inflammation therapy
decreasing the severity of AP.4.5. Limitations
Several limitations of this network meta-analysis must be
acknowledged. Some patients, equally distributed among the arms
within the studies, had undergone stent insertions. We were un-
able to examine the role of these stents due to the limited access to
data. Also, subjects in our pool had different a priori risks for
developing PEP (Sup Table 1).
Future subgroup analyses of patient individualized data from
RCTs could lead to more precise estimations with proper risk
stratification of patients. It is also known that older age (over 60)
brings significantly worse outcomes of pancreatitis [77,78]; how-
ever, we do not know if preventive efficacy is age-related. In the
studies analysed here, the mean age varied between 45 and 62.5. Conclusion
Our network meta-analysis shows that indomethacin and hy-
dration has an additive effect over each treatment alone in PEP
prevention. A combination of these therapies should be applied
(Table 3). For liquid replacement there is no absolute contraindi-
cation. For indomethacin contraindications comprise allergy and
kidney failure.5.1. Implementation to research
Although the result of this analysis are already quite convincing
with regard to which (combination of) therapy(ies) should be used
to prevent PEP, there are some limitations to this network meta-
analysis that were already addressed above. In order to address
these limitations and to develop evidence-based level I recom-
mendations, an adequately powered multicentre RCT should be
designed and executed.5.2. Implementation to practice
This network meta-analysis suggests that a combination ther-
apy of i.v. fluid replacement and NSAID, i.c. lactated Ringer's and
rectal indomethacin, is superior in preventing PEP compared to
either other combination or single therapy.
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